Stockscreener 앱 받기
1.28
3.64%
0.045
전일 마감가:
$1.235
열려 있는:
$1.26
하루 거래량:
58,861
Relative Volume:
0.43
시가총액:
$13.71M
수익:
-
순이익/손실:
$-9.70M
주가수익비율:
-1.1636
EPS:
-1.1
순현금흐름:
$-8.57M
1주 성능:
-16.34%
1개월 성능:
-25.58%
6개월 성능:
-54.12%
1년 성능:
-71.11%
1일 변동 폭
$1.20
$1.30
1주일 범위
$1.13
$1.64
52주 변동 폭
$1.13
$5.99
마커 테라퓨틱스 Stock (MRKR) Company Profile
명칭
Marker Therapeutics Inc
전화
(713) 400-6400
주소
2450 HOLCOMBE BLVD, HOUSTON, TX
MRKR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.28 | 13.71M | 0 | -9.70M | -8.57M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
513.76 | 131.93B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
678.42 | 74.17B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.19 | 37.32B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.11 | 32.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
265.07 | 28.49B | 3.32B | -860.46M | -1.04B | -8.32 |
마커 테라퓨틱스 Stock (MRKR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 개시 | Canaccord Genuity | Buy |
| 2021-03-25 | 개시 | Piper Sandler | Overweight |
| 2021-03-19 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-05-12 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2019-05-30 | 개시 | ROTH Capital | Buy |
| 2019-03-01 | 개시 | Janney | Buy |
| 2018-12-03 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
마커 테라퓨틱스 주식(MRKR)의 최신 뉴스
Marker Therapeutics (MRKR) to Release Earnings on Monday - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
MRKR stock touches 52-week low at $1.35 amid market challenges - Investing.com Australia
MRKR stock touches 52-week low at $1.35 amid market challenges By Investing.com - Investing.com South Africa
Canaccord Genuity Group Initiates Coverage on Marker Therapeutics (NASDAQ:MRKR) - Defense World
Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga India
Canaccord Genuity Initiates Coverage of Marker Therapeutics (MRKR) with Buy Recommendation - Nasdaq
Marker Therapeutics initiated with a Buy at Canaccord - TipRanks
MRKR stock touches 52-week low at $1.45 amid market challenges - Investing.com India
MRKR stock touches 52-week low at $1.45 amid market challenges By Investing.com - Investing.com South Africa
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewswire
Will Marker Therapeutics Reveal New Clinical Data at Upcoming Cell Therapy Conference? - StockTitan
MRKR stock touches 52-week low at $1.48 amid market challenges - Investing.com India
MRKR stock touches 52-week low at $1.48 amid market challenges By Investing.com - Investing.com South Africa
Marker Therapeutics grants stock options to CEO and directors By Investing.com - Investing.com South Africa
Marker Therapeutics grants stock options to CEO and directors - Investing.com India
Marker Therapeutics (MRKR) Stock Price, News & Analysis - MarketBeat
Analysts Offer Predictions for MRKR FY2024 Earnings - Defense World
Marker Therapeutics (NASDAQ:MRKR) Upgraded at Brookline Capital Management - Defense World
Brookline Capital sets $4 target on Marker Therapeutics stock - MSN
MRKR stock touches 52-week low at $1.61 amid market challenges - Investing.com Nigeria
Brookline Capital sets $4 target on Marker Therapeutics stock By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy on OKYO Pharma with $7 target - MSN
MRKR stock touches 52-week low at $1.61 amid market challenges By Investing.com - Investing.com South Africa
Marker Therapeutics (NASDAQ:MRKR) Stock Price Down 2.8% – Here’s Why - Defense World
Cytokinetics draws new Buy from Citi on aficamten potential - MSN
Biotech Analysis Central Model 10+ Portfolio Pick#16 Marker Therapeutics; MT-601 Lymphoma Data 2nd Half Of 2024, Study Initiation Of OTS MT-401 For AML And Catalysts (NASDAQ:MRKR) - Seeking Alpha
Marker Therapeutics Announces Board Resignation - MSN
MRKR stock touches 52-week low at $1.8 amid market challenges - MSN
Marker Therapeutics Announces Board Resignation By Investing.com - Investing.com Nigeria
Marker Therapeutics pops on receiving $9.5M grant to advance lead asset - MSN
Hematopoietic Stem Cell Transplantation Market: Soaring - openPR
MRKR stock touches 52-week low at $2.4 amid challenging year - MSN
MRKR stock touches 52-week low at $2.4 amid challenging year By Investing.com - Investing.com South Africa
Marker Therapeutics (NASDAQ:MRKR) Shares Down 7.5% – What’s Next? - Defense World
SEC Form 424B3 filed by Marker Therapeutics Inc. - Quantisnow
BostonGene Evaluates Novel Therapies and Immune System Profiling as a Marker of Response in Patients with Gastrointestinal Cancers - Business Wire
마커 테라퓨틱스 (MRKR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.59%
3.17%
자본화:
|
볼륨(24시간):